Biomarin Pharmaceutical
- Country
- 🇨🇦Canada
- Ownership
- -
- Established
- 1997-01-01
- Employees
- -
- Market Cap
- $17.2B
- Website
- http://www.biomarin.com
A Study to Evaluate Seroprevalence and Seroconversion of Antibodies to Adeno-Associated Virus (AAV) in Patients With Hemophilia A
- Conditions
- Hemophilia A
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 186
- Registration Number
- NCT04560933
- Locations
- 🇺🇸
Covance Inc, Madison, Wisconsin, United States
A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia
- First Posted Date
- 2020-09-18
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 20
- Registration Number
- NCT04554940
- Locations
- 🇦🇺
Murdoch Children's Research Institute, Parkville, Victoria, Australia
🇬🇧Guy's and St. Thomas NHS Foundation Trust Evelina Children's Hospital, London, United Kingdom
🇬🇧Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdom
AAV Gene Therapy Study for Subjects with PKU
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 100
- Registration Number
- NCT04480567
- Locations
- 🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸Morristown Medical Center, Morristown, New Jersey, United States
🇬🇧University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Cerliponase Alfa Observational Study in the US
- Conditions
- Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
- Interventions
- Device: Administration Kit
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 35
- Registration Number
- NCT04476862
- Locations
- 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸Children's Hospital of Colorado, Aurora, Colorado, United States
A Prospective Clinical Study of Phenylketonuria (PKU)
- Conditions
- Phenylketonurias
- First Posted Date
- 2020-06-30
- Last Posted Date
- 2023-03-14
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 32
- Registration Number
- NCT04452513
- Locations
- 🇺🇸
Children's Hosptial of Colorado, Aurora, Colorado, United States
🇺🇸University of Florida, Gainesville, Florida, United States
🇺🇸University of South Florida, Tampa, Florida, United States
Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A
- Conditions
- Hemophilia A
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 22
- Registration Number
- NCT04323098
- Locations
- 🇺🇸
University of California Davis Health, Sacramento, California, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
- Conditions
- Achondroplasia
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 73
- Registration Number
- NCT03989947
- Locations
- 🇺🇸
Children's Hospital & Research Center Oakland, Oakland, California, United States
🇺🇸Harbor - UCLA Medical Center, Torrance, California, United States
🇺🇸Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States
Lifetime Impact Study for Achondroplasia
- Conditions
- Achondroplasia
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2021-04-05
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 173
- Registration Number
- NCT03872531
- Locations
- 🇦🇷
Hospital de Pediatría "Prof. Dr. Juan P. Garrahan", Buenos Aires, Argentina
🇧🇷Instituto Nacional Fernandes Figueira (IFF), Fundacao Osvaldo Cruz, Rio de Janeiro, Brazil
🇧🇷Centro de Pesquisa Clínica do Instituto da Criança HC - FMUSP, São Paulo, Brazil
Retrospective Observational Safety Effectiveness With Kuvan in hpA
- Conditions
- Tetrahydrobiopterin Deficiency
- First Posted Date
- 2019-03-06
- Last Posted Date
- 2019-03-07
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 26
- Registration Number
- NCT03864029
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKU
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 37
- Registration Number
- NCT03694353
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸University of South Florida, Tampa, Florida, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States